PDCD1 and myeloid sarcoma: We detected an increase in PD-1+ pro-inflammatory T cell subsets, whereas PD-1+ regulatory T cells were reduced in MS patients as compared to controls (Fig. 2B and C and Supplementary Fig. 3A).